CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Richard Small, CEO of Neurotech Pharmaceuticals, provides a company update ahead of the American Academy of Ophthalmology Meeting.
Neurotech submitted a biologics license application for its macular telangiectasia therapy, NT-501, to the FDA in April, Small said. As Healio previously reported, NT-501 was granted priority review by the FDA in June. The therapy’s PDUFA review date is set for December of this year.
The company is also hosting a new medical education program at their AAO exposition booth this year, which